Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CervoMed Inc CRVO

Healthcare Biotechnology
CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related neurologic disorders. It is focused on the development of its lead drug candidate, neflamapimod, an investigational, orally administered, small molecule brain penetrant that inhibits p38a in the neurons (nerve cells) within the brains of people with neurodegenerative diseases. Its... see more

Recent & Breaking News (NDAQ:CRVO)

CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies

GlobeNewswire June 11, 2024

CervoMed to Appoint William Elder as Chief Financial Officer

GlobeNewswire May 20, 2024

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

GlobeNewswire May 15, 2024

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

GlobeNewswire April 1, 2024

CervoMed to Participate in Upcoming Investor Conferences

GlobeNewswire March 28, 2024

CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

GlobeNewswire March 28, 2024

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD (TM) 2024

GlobeNewswire March 5, 2024

CervoMed to Participate in the BIO CEO and Investor Conference

GlobeNewswire February 21, 2024

CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies

GlobeNewswire February 12, 2024

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

GlobeNewswire February 7, 2024

CervoMed to Participate in the Emerging Growth Conference 67

GlobeNewswire February 5, 2024

CervoMed to Participate in the Emerging Growth Conference 66

GlobeNewswire January 5, 2024

CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights

PR Newswire November 13, 2023

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy Bodies

PR Newswire October 25, 2023

CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias

PR Newswire October 24, 2023

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy Bodies

PR Newswire October 18, 2023

CervoMed to Present at the 2023 Roth Healthcare Opportunities Conference

PR Newswire October 5, 2023

CervoMed to Present at H.C. Wainwright 25th Annual Global Investment Conference

PR Newswire September 5, 2023